MY135972A - Egg anti-inflammatory composition and method of treating and preventing inflammation - Google Patents

Egg anti-inflammatory composition and method of treating and preventing inflammation

Info

Publication number
MY135972A
MY135972A MYPI99004327A MYPI994327A MY135972A MY 135972 A MY135972 A MY 135972A MY PI99004327 A MYPI99004327 A MY PI99004327A MY PI994327 A MYPI994327 A MY PI994327A MY 135972 A MY135972 A MY 135972A
Authority
MY
Malaysia
Prior art keywords
treating
inflammatory composition
composition
preventing inflammation
egg
Prior art date
Application number
MYPI99004327A
Inventor
Lee R Beck
Orn Adalsteinsson
Michael J Daley
Sandra G Fitzpatrick-Mcelligott
Hellen Chaya Greenblatt
Jeffrey G Hunchar
Young-Zoon Lee
Subramanian Iyer
Ruye Xing
Original Assignee
Arkion Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkion Life Sciences filed Critical Arkion Life Sciences
Publication of MY135972A publication Critical patent/MY135972A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1292—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Abstract

THE INVENTION IS DIRECTED TO A COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATION IN GENERAL. THE COMPOSITION IS AN EGG PRODUCT OBTAINED FROM AN AVIAN WHICH HAS BEEN HYPERIMMUNIZED WITH NO IMMUNOGENIC MIXTURE. THE INVENTION IS FURTHER DIRECTED TO AN ANTI-INFLAMMATORY COMPOSITION WHICH HAS BEEN PARTIALLY PURIFIED FROM A HYPERIMMUNIZED EGG.THE PARTIALLY PURIFIED ANTI-INFLAMMATORY COMPOSITION, WHEN ADMINISTERED TO A SUBJECT ANIMAL IS EFFECTIVE IN TREATING AND PREVENTING INFLAMMATION.
MYPI99004327A 1999-01-19 2000-01-07 Egg anti-inflammatory composition and method of treating and preventing inflammation MY135972A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23337999A 1999-01-19 1999-01-19

Publications (1)

Publication Number Publication Date
MY135972A true MY135972A (en) 2008-07-31

Family

ID=22876994

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99004327A MY135972A (en) 1999-01-19 2000-01-07 Egg anti-inflammatory composition and method of treating and preventing inflammation

Country Status (8)

Country Link
EP (1) EP1143984A1 (en)
JP (1) JP2002535279A (en)
KR (1) KR100789488B1 (en)
AU (3) AU2372400A (en)
CA (1) CA2355168A1 (en)
MY (1) MY135972A (en)
NZ (1) NZ502421A (en)
WO (2) WO2000043019A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474360A1 (en) 2002-02-11 2003-08-21 Arkion Life Sciences Llc Purified cytokine inhibitory factor
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AR086437A1 (en) 2011-10-13 2013-12-11 Aixela Juan Cunill PREPARED EGG WITH REGENERATING, ANALGESIC AND / OR ANTI-INFLAMMATORY PROPERTIES
ITMI20121076A1 (en) * 2012-06-20 2013-12-21 Giellepi S P A COMPOSITION FOR LOCAL USE IN TREATMENT OF TISSUE DAMAGE
RO130213A8 (en) * 2014-10-29 2017-06-30 Romvac Company S.A. Production and use of hyperimmune egg - pc2
WO2018043450A1 (en) * 2016-08-29 2018-03-08 株式会社クレスト Method for separating low-molecular component from egg, composition containing low-molecular component, and device therefor
MX2019009554A (en) 2017-02-13 2020-01-30 Us Agriculture Hyperimmunized egg product for treatment of necrotic enteritis in poultry.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0499728A (en) * 1990-08-20 1992-03-31 Nippon Nousan Kogyo Kk Composition having anti-inflammatory action
DE69530910T4 (en) * 1994-07-15 2005-07-14 Taiyo Kagaku Co., Ltd., Yokkaichi MEDICAL COMPOSITIONS CONTAINING A SIALINIC ACID DERIVATIVE
KR20000004990A (en) * 1996-03-26 2000-01-25 마크 제이. 건더슨 Anti-inflammatory composition of egg, isolation method and use thereof
US5772999A (en) * 1996-07-30 1998-06-30 Dcv Biologics, L.P. Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals
JP2002509109A (en) * 1998-01-19 2002-03-26 ディーシーヴィー インコーポレイテッド Compositions and methods for treating and preventing arthritis and / or autoimmune diseases

Also Published As

Publication number Publication date
NZ502421A (en) 2001-09-28
KR20010101565A (en) 2001-11-14
KR100789488B1 (en) 2007-12-28
EP1143984A1 (en) 2001-10-17
AU1248400A (en) 2000-07-20
WO2000043019A2 (en) 2000-07-27
AU2372400A (en) 2000-08-07
AU2389800A (en) 2000-08-07
CA2355168A1 (en) 2000-07-27
AU767570B2 (en) 2003-11-13
WO2000043020A1 (en) 2000-07-27
JP2002535279A (en) 2002-10-22

Similar Documents

Publication Publication Date Title
WO2002085303A3 (en) Substituted tetracycline compounds for the treatment of malaria
DE69909818D1 (en) PYRAZOLOPYIMIDINONE DERIVATIVES FOR TREATING IMPOTENCE
BR9502707A (en) Compound pharmaceutical composition and method for treating a condition
DE69733132D1 (en) USE OF ANTIOXIDANTS FOR THE TREATMENT OF CHOLESTATIVE LIVER DISEASES
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
UA56989C2 (en) PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES
ATE101515T1 (en) USE OF A COMPOSITION FOR THE MANUFACTURE OF A MEDICATION FOR TREATMENT OF SYMPTOMS OF ABSENCE.
PT746327E (en) ACIDIFIED NITRITE AS AN ANTIMICROBIAL AGENT
PT758241E (en) USE OF CERTAIN METHANBOSPHOSPHONIC ACID DERIVATIVES TO PREVENT THE DISPOSAL OF PROTESES AND PROTEIN MIGRATION
WO2004038001A3 (en) Substituted tetracycline compounds for the treatment of malaria
ATE263572T1 (en) USE OF GASTRIN FRAGMENTS OR SYTHETICAL ANALOGUES OF GASTRIN FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HELICOBACTER PYLORI ASSOCIATED DISORDERS
RU99107569A (en) PHARMACEUTICAL COMPOSITIONS Possessing Antimicrobial Activity
BR9500436A (en) Products use of a g-csf use of a tnf protein ligand process for the treatment and / or prevention of septic shock
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
MY135972A (en) Egg anti-inflammatory composition and method of treating and preventing inflammation
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
MXPA01011924A (en) Methods and compositions for modulating immune response and for the treatment of inflammatory disease.
ATE229518T1 (en) CIS-3,4-CHROMAN DERIVATIVES FOR THE PREVENTION OR TREATMENT OF ESTROGEN-RELATED DISEASES OR SYNDROMES
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
BG103512A (en) Substituted pyramidine compounds and their application
WO2001035902A3 (en) Stabilized thyroxine compounds
EP0835662A3 (en) A drug for the treatment of cancer
ATE302011T1 (en) PONAZURIL FOR THE TREATMENT OF DISEASES CAUSED BY COCCIDIA NEUROLOGICAL AND ABORTIGENICS
ES2101100T3 (en) A PRODUCT FOR THE TREATMENT OF LIVER CANCER AND ITS MANUFACTURING PROCEDURE.